NCT05451212 - Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2028

Conditions

MuSK Myasthenia Gravis

Interventions

BIOLOGICAL

MuSK-CAART

Intravenous infusion of MuSK-CAART at different doses. Subjects may also receive MuSK-CAART following pre-treatment with CY, or CY plus FLU.

Trial Locations (5)

RECRUITING

University of Kansas Medical Center, Kansas City

ACTIVE_NOT_RECRUITING

Houston Methodist Hospital, Houston

RECRUITING

UC Irvine, Department of Neurology, Orange

RECRUITING

UC Davis, Department of Neurology, Sacramento

RECRUITING

Oregon Health & Science University (OHSU), Portland